Clinical and Biochemical Recovery From Immune Checkpoint Inhibitor-Induced Diabetes With Seroconversion of GAD Antibodies.
Lillian Ruiheng Chen, Tim Cooksley, Rupinder Kochhar et al.
✦ AI-curated · Sources linked
Case in brief
A patient with melanoma developed abrupt-onset symptomatic hyperglycemia and mild ketosis after treatment with ipilimumab and nivolumab, indicating immune checkpoint inhibitor-induced diabetes (ICI-D). Following infliximab treatment for ICI-related arthritis, the patient's insulin requirements decreased, leading to the discontinuation of insulin therapy. GAD antibodies normalized within approximately two months, and urine C-peptide levels indicated recovery of endogenous insulin secretion.
Diagnostic / clinical pearl
Clinicians should be aware that recovery from immune checkpoint inhibitor-induced diabetes can occur, as evidenced by normalization of GAD antibodies and increased endogenous insulin secretion.
Why it matters
This case highlights the potential for disease modification in ICI-D, suggesting that treatments like infliximab may influence recovery and warrant further investigation.